Edoxaban (tosylate Monohydrate) CAS 1229194-11-9

Product Description:

Product Name: Edoxaban (tosylate Monohydrate) CAS NO: 1229194-11-9

Synonyms:

Edoxaban tosylate monohydrate;

N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide,4-methylbenzenesulfonic acid,hydrate;

4-methylbenzene-1-sulfonicacid,N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-{5-methyl-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridine-2-amido}cyclohexyl]ethanediamide hydrate;

Chemical & Physical Properties:

Appearance: Solid powder

Assay :≥99.00%

Exact Mass: 737.206848

Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. Daichi Sankyo’s edoxaban tosilate is an orally administered coagulation factor Xa inhibitor that was approved and launched in Japan for the preventive treatment of venous thromboembolic events (VTE) in patients undergoing total knee arthroplasty, total hip arthroplasty, or hip fracture surgery. Edoxaban has been shown to have a rapid onset of anticoagulant effect due to short Tmax (1–2 h) after dosing and sustained for up to 24 h post-dose. Marketed under the brand name Lixiana, it is currently in phase III studies in the US for the prevention of stroke and systemic embolic events in patients with atrial fibrillation (AF) and venous thromboembolism (VTE).

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.